Othon Iliopoulos, MD, PhD is an Associate Professor of Medicine at Harvard Medical School (HMS) and Massachusetts General Hospital Cancer Center (MGHCC). He is a co-leader of the Kidney Cancer Program of the Dana-Farber/Harvard Cancer Center and member of the DF/HCC Research Council.
He graduated from The National and Kapodistrian University School of Medicine, in Athens, Greece. He trained in Internal Medicine at Johns Hopkins University and University of Wisconsin Medical School and he completed his medical oncology fellowship at Dana-Farber Cancer Institute and Harvard Medical School. He is board certified in both Internal Medicine and Medical Oncology.
Currently he is an attending physician at Massachusetts General Hospital Cancer Center and the director of the Hereditary Genitourinary Program at the division of Hematology Oncology and the Hemangioblstoma Center at the Department of Neuro-Oncology, all at MGH.
His laboratory of Cancer Genetics at MGHCC studies basic mechanisms of cancer metabolism and hypoxia signaling in cancer cells, with an interest in identifying and validating therapeutic targets that can inform rational design of clinical trials.